FYERS
Ishita Drugs & Industries71.15
+0.15 (+0.21%)

Ishita Drugs & Industries Share Price

71.15+0.15 (+0.21%)
-12.19% past 1 Year

Corporate filings & documents

Announcements

Ishita Drugs & Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/09/2026 inter alia to consider and approve 1. To consider and approve raising of funds by the Company by way of working capital and project term loan facilities and to approve the terms and conditions for the same.2. Any other matter with permission of the Chair.
3 days ago
Ishita Drugs & Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/09/2026 inter alia to consider and approve 1. To consider and approve raising of funds by the Company by way of working capital and project term loan facilities and to approve the terms and conditions for the same.2. Any other matter with permission of the Chair.
3 days ago
Company has issued letters providing a weblink of Companys website to access Annual report for Financial Year 2025-26 to those members who have not registered their email addresses.
3 weeks ago
Company has issued letters providing a weblink of Companys website to access Annual report for Financial Year 2025-26 to those members who have not registered their email addresses.
3 weeks ago
Annual Report for the Financial Year 2025-26 including Notice of 33rd Annual General Meeting of the Company to be held on 30.09.2026.
3 weeks ago
Annual Report for the Financial Year 2025-26 including Notice of 33rd Annual General Meeting of the Company to be held on 30.09.2026.
3 weeks ago
Notice of 33RD AGM of the Company which will be held on wednesday 30th September 2026 and E voting period for AGM commence from 27.09.2026 (09:00 a.m. IST) and ends on 29.09.2026 (5:00 p.m. IST)
3 weeks ago
Notice of 33RD AGM of the Company which will be held on wednesday 30th September 2026 and E voting period for AGM commence from 27.09.2026 (09:00 a.m. IST) and ends on 29.09.2026 (5:00 p.m. IST)
3 weeks ago
The E-voting period for ensuing 33rd AGM which is to be held on 30.09.2026 will commence from 27.09.2026 (09:00 a.m. IST) and ends on 29.09.2026 (05:00 p.m. IST) (Both days inclusive).
3 weeks ago
The E-voting period for ensuing 33rd AGM which is to be held on 30.09.2026 will commence from 27.09.2026 (09:00 a.m. IST) and ends on 29.09.2026 (05:00 p.m. IST) (Both days inclusive).
3 weeks ago
Register of Members and Share transfer book of the Company will remain closed from 24.09.2026 to 30.09.2026 (Both days Inclusive) for the purpose of 33rd Annual General Meeting of the Company.
3 weeks ago
Register of Members and Share transfer book of the Company will remain closed from 24.09.2026 to 30.09.2026 (Both days Inclusive) for the purpose of 33rd Annual General Meeting of the Company.
3 weeks ago
Re-appointment of Mrs. Abha Agrawal (DIN: 01589479) as a Non -executive Non- Inependent Director of the Company post attaining the age of 75 years.
1 month ago
Re-appointment of Mrs. Abha Agrawal (DIN: 01589479) as a Non -executive Non- Inependent Director of the Company post attaining the age of 75 years.
1 month ago
Unaudited Financial Results of the Compmany for the quarter ended 30th June 2026 along with limited review report issued by statutory auditor.
1 month ago
Unaudited Financial Results of the Compmany for the quarter ended 30th June 2026 along with limited review report issued by statutory auditor.
1 month ago
Outcome of the Board meeting held on 08th August 2026.
1 month ago
Outcome of the Board meeting held on 08th August 2026.
1 month ago
Ishita Drugs & Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2026 inter alia to consider and approve 1. To consider approve and take on record the Unaudited Financial Results of the Company for the quarter ended 30th June 2026.2. Any other matter with permission of the Chair.
1 month ago
Ishita Drugs & Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2026 inter alia to consider and approve 1. To consider approve and take on record the Unaudited Financial Results of the Company for the quarter ended 30th June 2026.2. Any other matter with permission of the Chair.
1 month ago
Compliance Certificate under regulation 74(5) of SEBI (DP) Regulations 2018 for the quarter ended 30th June 2026 as attached.
2 months ago
Compliance Certificate under regulation 74(5) of SEBI (DP) Regulations 2018 for the quarter ended 30th June 2026 as attached.
2 months ago
The trading window for dealing in securities of the Company by designated persons stands closed from Wednesday 1st July 2026 till 48 hours after the declaration of the Unaudited Financial Results for the quarter ended 30th June 2026 .
2 months ago
The trading window for dealing in securities of the Company by designated persons stands closed from Wednesday 1st July 2026 till 48 hours after the declaration of the Unaudited Financial Results for the quarter ended 30th June 2026 .
2 months ago
Disclosure under regulation 29(2) of SEBI(SAST) Regulations 2011 received from Ishita Pharmaceuticals related party of Ishita Drugs and Industries Limited.
2 months ago
Disclosure under regulation 29(2) of SEBI(SAST) Regulations 2011 received from Ishita Pharmaceuticals related party of Ishita Drugs and Industries Limited.
2 months ago
Disclosure under regulation 29(2) of SEBI (SAST) Regulations 2011 received from Ishita Pharmaceuticals related party of ishita Drugs and Industries Limited.
3 months ago
Disclosure under regulation 29(2) of SEBI (SAST) Regulations 2011 received from Ishita Pharmaceuticals related party of ishita Drugs and Industries Limited.
3 months ago
Audited Financial Results for the quarter and year ended 31st March 2026
3 months ago
Audited Financial Results for the quarter and year ended 31st March 2026
3 months ago
Outcome of Board Meeting held on 30th May 2026
3 months ago
Outcome of Board Meeting held on 30th May 2026
3 months ago
Ishita Drugs & Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 inter alia to consider and approve 1. To consider approve and take on records the Audited Financial Results of the Company for the quarter and year ended 31st March 2026 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. 2. To consider and approve the Directors Report with the Annexure Corporate Governance Report Management Discussion and Analysis Report and Notice for convening the 33rd Annual General Meeting of the Company.3. To consider the re-appointment of Internal Auditors of the Company for the year 2026-27.4. To take on record Disclosure of Interest of Directors.5. Any other matter with permission of the Chair.
4 months ago
The meeting of the Board of Directors of the Company will be held on Saturday 30th May 2026 to transact the following business:1. To consider and take on records the Audited Financial Results of the Company fo the quarter and year ended 31st March 2026 pursunt to regulation 33 of the SEBI (LODR) Regulations 2015.2. To consider and approve the Directors Report with Annexures and Notice for convening the 33rd AGM of the Company.3. To consider the re-appointment of internal Auditors of the Company for the year 2026-27.4. To take on record Disclosure of Interest of Directors.5. Any other matter with the permission of the chair.
4 months ago
The meeting of the Board of Directors of the Company will be held on Saturday 30th May 2026 to transact the following business:1. To consider and take on records the Audited Financial Results of the Company fo the quarter and year ended 31st March 2026 pursunt to regulation 33 of the SEBI (LODR) Regulations 2015.2. To consider and approve the Directors Report with Annexures and Notice for convening the 33rd AGM of the Company.3. To consider the re-appointment of internal Auditors of the Company for the year 2026-27.4. To take on record Disclosure of Interest of Directors.5. Any other matter with the permission of the chair.
4 months ago
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Ishita Drugs & Industries Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24231GJ1992PLC017054</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.14</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Srushti Pandya <br/> Designation: Company Secretary <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Sumit Agrawal <br/> Designation: Chief Financial Officer <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 28/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months ago
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Ishita Drugs & Industries Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24231GJ1992PLC017054</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.14</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Srushti Pandya <br/> Designation: Company Secretary <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Sumit Agrawal <br/> Designation: Chief Financial Officer <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 28/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months ago
Non-Applicability of Annual Secretarial Compliance Certificate for the year ended 31st March 2026
5 months ago
Non-Applicability of Annual Secretarial Compliance Certificate for the year ended 31st March 2026
5 months ago
Non - applicability of Regulation 32(1) of SEBI(LODR) Regulations 2015 for the year ended 31st March 2026.
5 months ago
Non - applicability of Regulation 32(1) of SEBI(LODR) Regulations 2015 for the year ended 31st March 2026.
5 months ago
Complaince Certificate under Regulation 74(5) of SEBI (DP) Regulations 2018 for the quarter ended 31st March 2026 as attached.
5 months ago
The trading window for dealing in securities of the Company by designated persons stands closed from Wednesday 01st April 2026 till 48 hours after the declaration of the Audited Financial Results for the quarter and Financial year ended 31st March 2026.
5 months ago
The trading window for dealing in securities of the Company by designated persons stands closed from Wednesday 01st April 2026 till 48 hours after the declaration of the Audited Financial Results for the quarter and Financial year ended 31st March 2026.
5 months ago
Disclosure under regulation 29(2) of SEBI(SAST) Regulations 2011 received from Ishita Pharmaceuticals related party of Ishita Drgs and Industrie Limited.
6 months ago
Disclosure under regulation 29(2) of SEBI(SAST) Regulations 2011 received from Ishita Pharmaceuticals related party of Ishita Drgs and Industrie Limited.
6 months ago
Disclosure under regulation 29(2) of SEBI(SAST)Regulations 2011 received from Ishita Pharmaceuticals related party of Ishita Drugs and Industries Limited.
6 months ago
Disclosure under regulation 29(2) of SEBI(SAST)Regulations 2011 received from Ishita Pharmaceuticals related party of Ishita Drugs and Industries Limited.
6 months ago
Disclosure under regulation 29(2) of SEBI (SAST) Regulations 2011 received from Ishita Pharmaceuticals related party of Ishita Drugs and Industries Limited.
7 months ago
Disclosure under regulation 29(2) of SEBI (SAST) Regulations 2011 received from Ishita Pharmaceuticals related party of Ishita Drugs and Industries Limited.
7 months ago

Annual reports

FY 2023-24
FY 2022-23
FY 2021-22
FY 2020-21

Concalls & investor presentations

Empty box

No presentations found

Ishita Drugs & Industries Ltd Share Price Today

The Ishita Drugs & Industries Ltd share price today is ₹74.00. During the trading session, the Ishita Drugs & Industries Ltd share price opened at ₹74.00 and recorded an intraday high of ₹74.00 and a low of ₹74.00. Last closing price was ₹72.90. Over the past 52 weeks, the Ishita Drugs & Industries Ltd share price has ranged between ₹66.00 and ₹90.85. The current Ishita Drugs & Industries Ltd stock price reflects real-time market activity based on executed trades on the exchange.